Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 608

1.

Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.

Okomo-Adhiambo M, Sleeman K, Lysén C, Nguyen HT, Xu X, Li Y, Klimov AI, Gubareva LV.

Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.

2.

Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.

Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H.

Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003. Epub 2013 Jun 17.

PMID:
23791870
3.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.

Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M.

Antiviral Res. 2015 May;117:27-38. doi: 10.1016/j.antiviral.2015.02.003. Epub 2015 Feb 23.

4.

Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.

Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI.

Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.

PMID:
21149922
5.

In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.

J Infect Chemother. 2015 Sep;21(9):634-8. doi: 10.1016/j.jiac.2015.05.004. Epub 2015 May 30.

PMID:
26096495
6.

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV.

Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005. Epub 2009 Nov 13.

PMID:
19917319
7.

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14.

8.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.

Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, Gregory V, Gubareva L, Kageyama T, Lackenby A, Lo J, Odagiri T, Pereyaslov D, Siqueira MM, Takashita E, Tashiro M, Wang D, Wong S, Zhang W, Daniels RS, Hurt AC.

Antiviral Res. 2014 Oct;110:31-41. doi: 10.1016/j.antiviral.2014.07.001. Epub 2014 Jul 17.

9.

In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.

Ikematsu H, Kawai N, Kashiwagi S.

J Infect Chemother. 2012 Aug;18(4):529-33. doi: 10.1007/s10156-012-0377-8. Epub 2012 Feb 28.

PMID:
22370919
10.

Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.

Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D, Guigon A, Harrower B, Kei IP, Kok T, Lin C, McPhie K, Mohd A, Olveda R, Panayotou T, Rawlinson W, Scott L, Smith D, D'Souza H, Komadina N, Shaw R, Kelso A, Barr IG.

Antiviral Res. 2009 Jul;83(1):90-3. doi: 10.1016/j.antiviral.2009.03.003. Epub 2009 Mar 24.

PMID:
19501261
11.

In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.

J Infect Chemother. 2015 Jan;21(1):39-42. doi: 10.1016/j.jiac.2014.08.030. Epub 2014 Sep 30.

PMID:
25277670
12.

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

McKimm-Breschkin JL.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:25-36. doi: 10.1111/irv.12047. Review.

13.

Characterization of human Influenza Viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons.

Zaraket H, Dapat C, Ghanem S, Ali Z, Lteif M, Kondo H, Dapat IC, Saito K, Kayali G, Suzuki H, Dbaibo G, Saito R.

Intervirology. 2014;57(6):344-52. doi: 10.1159/000365758. Epub 2014 Oct 3.

PMID:
25301400
14.

Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.

Wang D, Sleeman K, Huang W, Nguyen HT, Levine M, Cheng Y, Li X, Tan M, Xing X, Xu X, Klimov AI, Gubareva LV, Shu Y.

Antiviral Res. 2013 Mar;97(3):240-4. doi: 10.1016/j.antiviral.2012.12.013. Epub 2012 Dec 23.

PMID:
23267831
15.

Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.

Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki H.

J Infect Chemother. 2012 Dec;18(6):858-64. doi: 10.1007/s10156-012-0428-1. Epub 2012 May 29.

PMID:
22644080
16.

Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.

Baek YH, Song MS, Lee EY, Kim YI, Kim EH, Park SJ, Park KJ, Kwon HI, Pascua PN, Lim GJ, Kim S, Yoon SW, Kim MH, Webby RJ, Choi YK.

J Virol. 2015 Jan;89(1):287-99. doi: 10.1128/JVI.02485-14. Epub 2014 Oct 15.

18.

Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.

Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6. doi: 10.1128/AAC.01364-13. Epub 2013 Sep 30.

19.

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.

Marjuki H, Mishin VP, Sleeman K, Okomo-Adhiambo M, Sheu TG, Guo L, Xu X, Gubareva LV.

Antimicrob Agents Chemother. 2013 Nov;57(11):5209-15. doi: 10.1128/AAC.01086-13. Epub 2013 Aug 5.

20.

Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.

Kossyvakis A, Mentis AA, Tryfinopoulou K, Pogka V, Kalliaropoulos A, Antalis E, Lytras T, Meijer A, Tsiodras S, Karakitsos P, Mentis AF.

Eur J Clin Microbiol Infect Dis. 2017 Feb;36(2):361-371. doi: 10.1007/s10096-016-2809-3. Epub 2016 Nov 15.

PMID:
27848039

Supplemental Content

Support Center